Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens

Patent metadata

Field	Value
Publication number	US-11338030-B2
Application number	US-202016802805-A
Country	US
Kind code	B2
Filing date	Feb 27, 2020
Priority date	Sep 3, 2014
Publication date	May 24, 2022
Grant date	May 24, 2022

Abstract

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.

First claim

The invention claimed is:

1. A recombinant MVA vector comprising a first nucleic acid encoding at least one immunogenic protein of a MARV envelope glycoprotein (GP); a second nucleic acid encoding an immunogenic protein of Zaire Ebola virus (ZEBOV) envelope glycoprotein; a third nucleic acid encoding an immunogenic protein of Sudan Ebola virus (SEBOV) envelope glycoprotein; and a fourth nucleic acid encoding an immunogenic protein of Ebola virus Ivory Coast nucleoprotein.

2. The recombinant MVA vector of claim 1 , wherein the MARV envelope glycoprotein is full-length MARV-Musoke envelope glycoprotein.

3. The recombinant MVA vector of claim 1 , wherein the first nucleic acid encodes an immunogenic protein comprising the sequence set forth in SEQ ID NO:6.

4. The recombinant MVA vector of claim 3 , wherein the first nucleic acid comprises the sequence set forth in SEQ ID NO:5.

5. The recombinant MVA vector of claim 1 that comprises a nucleic acid encoding an immunogenic protein having a sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, SEQ ID NO:31, and SEQ ID NO:37.

6. The recombinant MVA vector of claim 1 that comprises a nucleic acid encoding an immunogenic protein comprising the sequence set forth in SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, or SEQ ID NO:31.

7. The recombinant MVA vector of claim 6 , wherein said nucleic acid comprises the sequence set forth in SEQ ID NO:5, SEQ ID NO:19, SEQ ID NO:28, or SEQ ID NO:30.

8. The recombinant MVA vector of claim 1 , wherein the administration provides protective immunity or a protective immune response in the subject.

9. The recombinant MVA vector of claim 1 , wherein the recombinant MVA vector comprises at least one nucleic acid encoding the sequences set forth in SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, and SEQ ID NO:31.

10. The recombinant MVA vector of claim 1 further comprising a nucleic acid encoding CD40L.

11. The recombinant MVA vector of claim 10 , wherein the CD40L comprises the amino acid sequence set forth in SEQ ID NO:10.

12. The recombinant MVA vector of claim 11 , wherein the nucleic acid encoding CD40L comprises the sequence set forth in SEQ ID NO:9.

Assignees

• Bavarian Nordic As

Inventors

• Volkmann Ariane
• Steigerwald Robin
• Hochrein Hubertus
• Dirmeier Ulrike
• Lauterbach Henning
• Hausmann Jürgen

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C12N2710/24143

  viral genome or elements thereof as genetic vector · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N2800/107

  for mammalian · CPC title